Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer.

Trivedi S, Wiber SC, El-Zimaity HM, Brubaker PL.

Am J Physiol Gastrointest Liver Physiol. 2012 Apr 15;302(8):G840-9. doi: 10.1152/ajpgi.00505.2011. Epub 2012 Feb 9.

2.

Translocation t(11;18)(q21;q21) in gastric B-cell lymphomas.

Toracchio S, Ota H, de Jong D, Wotherspoon A, Rugge M, Graham DY, Samani A, El-Zimaity HM.

Cancer Sci. 2009 May;100(5):881-7. doi: 10.1111/j.1349-7006.2009.01128.x. Epub 2009 Mar 23.

3.

Mycobacterium avium subspecies paratuberculosis and Crohn's disease granulomas.

Toracchio S, El-Zimaity HM, Urmacher C, Katz S, Graham DY.

Scand J Gastroenterol. 2008;43(9):1108-11. doi: 10.1080/00365520802116455.

PMID:
18609156
4.

Chromoendoscopy points the way to understanding recovery of gastric function after Helicobacter pylori eradication.

Graham DY, Shiotani A, El-Zimaity HM.

Gastrointest Endosc. 2006 Nov;64(5):686-90. Epub 2006 Sep 1. No abstract available.

PMID:
17055857
5.

Gastric atrophy, diagnosing and staging.

El-Zimaity HM.

World J Gastroenterol. 2006 Sep 28;12(36):5757-62. Review.

6.

Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection.

Graham DY, Abudayyeh S, El-Zimaity HM, Hoffman J, Reddy R, Opekun AR.

Aliment Pharmacol Ther. 2006 Sep 1;24(5):845-50.

7.

Co-localization of TFF2 with gland mucous cell mucin in gastric mucous cells and in extracellular mucous gel adherent to normal and damaged gastric mucosa.

Ota H, Hayama M, Momose M, El-Zimaity HM, Matsuda K, Sano K, Maruta F, Okumura N, Katsuyama T.

Histochem Cell Biol. 2006 Nov;126(5):617-25. Epub 2006 Jun 20.

PMID:
16786324
8.

Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America.

Graham DY, Nurgalieva ZZ, El-Zimaity HM, Opekun AR, Campos A, Guerrero L, Chavez A, Cardenas V.

Clin Gastroenterol Hepatol. 2006 Mar;4(3):306-14.

PMID:
16527693
9.

Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border.

Cardenas VM, Graham DY, El-Zimaity HM, Opekun AR, Campos A, Chavez A, Guerrero L.

Aliment Pharmacol Ther. 2006 Jan 15;23(2):295-301.

10.

Helicobacter pylori outer membrane proteins and gastroduodenal disease.

Yamaoka Y, Ojo O, Fujimoto S, Odenbreit S, Haas R, Gutierrez O, El-Zimaity HM, Reddy R, Arnqvist A, Graham DY.

Gut. 2006 Jun;55(6):775-81. Epub 2005 Dec 1.

11.

Atrophic gastritis in young children and adolescents.

Ricuarte O, Gutierrez O, Cardona H, Kim JG, Graham DY, El-Zimaity HM.

J Clin Pathol. 2005 Nov;58(11):1189-93.

12.

CagA in Barrett's oesophagus in Colombia, a country with a high prevalence of gastric cancer.

Kudo M, Gutierrez O, El-Zimaity HM, Cardona H, Nurgalieva ZZ, Wu J, Graham DY.

J Clin Pathol. 2005 Mar;58(3):259-62.

13.

Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori.

Graham DY, Opekun AR, Belson G, El-Zimaity HM, Carlson MR.

Aliment Pharmacol Ther. 2005 Jan 15;21(2):165-8.

14.

Interobserver variation in the histopathological assessment of malt/malt lymphoma: towards a consensus.

El-Zimaity HM, Wotherspoon A, de Jong D; Houston MALT lymphoma Workshop.

Blood Cells Mol Dis. 2005 Jan-Feb;34(1):6-16.

PMID:
15607694
15.

Challenge model for Helicobacter pylori infection in human volunteers.

Graham DY, Opekun AR, Osato MS, El-Zimaity HM, Lee CK, Yamaoka Y, Qureshi WA, Cadoz M, Monath TP.

Gut. 2004 Sep;53(9):1235-43.

16.

Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.

Graham DY, Belson G, Abudayyeh S, Osato MS, Dore MP, El-Zimaity HM.

Dig Liver Dis. 2004 Jun;36(6):384-7.

PMID:
15248377
17.

False negative urea breath tests with H2-receptor antagonists: interactions between Helicobacter pylori density and pH.

Graham DY, Opekun AR, Jogi M, Yamaoka Y, Lu H, Reddy R, El-Zimaity HM.

Helicobacter. 2004 Feb;9(1):17-27.

PMID:
15156900
18.

Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies.

Bochenek WJ, Peters S, Fraga PD, Wang W, Mack ME, Osato MS, El-Zimaity HM, Davis KD, Graham DY; Helicobacter pylori Pantoprazole Eradication (HELPPE) Study Group.

Helicobacter. 2003 Dec;8(6):626-42. Erratum in: Helicobacter. 2004 Apr;9(2):183.

PMID:
14632678
19.

Enterococcus gastritis.

El-Zimaity HM, Ramchatesingh J, Clarridge JE, Abudayyeh S, Osato MS, Graham DY.

Hum Pathol. 2003 Sep;34(9):944-5.

PMID:
14562292
20.

Helicobacter pylori and hetertopic gastric mucosa in the upper esophagus (the inlet patch).

Gutierrez O, Akamatsu T, Cardona H, Graham DY, El-Zimaity HM.

Am J Gastroenterol. 2003 Jun;98(6):1266-70.

PMID:
12818267
21.

Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors.

Graham DY, Opekun AR, Hammoud F, Yamaoka Y, Reddy R, Osato MS, El-Zimaity HM.

Am J Gastroenterol. 2003 May;98(5):1005-9.

PMID:
12809820
22.

Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication.

Graham DY, Hammoud F, El-Zimaity HM, Kim JG, Osato MS, El-Serag HB.

Aliment Pharmacol Ther. 2003 May 15;17(10):1229-36.

23.

Early events in proton pump inhibitor-associated exacerbation of corpus gastritis.

Graham DY, Opekun AR, Yamaoka Y, Osato MS, el-Zimaity HM.

Aliment Pharmacol Ther. 2003 Jan;17(2):193-200.

24.

New serological assay for detection of putative Helicobacter pylori virulence factors.

Park CY, Cho YK, Kodama T, El-Zimaity HM, Osato MS, Graham DY, Yamaoka Y.

J Clin Microbiol. 2002 Dec;40(12):4753-6.

25.

Genomic fingerprinting and genotyping of Helicobacter pylori strains from patients with duodenal ulcer or gastric cancer from different geographic regions.

Li L, Graham DY, Gutierrez O, Kim JG, Genta RM, El-Zimaity HM, Go MF.

Dig Dis Sci. 2002 Nov;47(11):2512-8.

PMID:
12452388
26.

Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island.

Hsu PI, Hwang IR, Cittelly D, Lai KH, El-Zimaity HM, Gutierrez O, Kim JG, Osato MS, Graham DY, Yamaoka Y.

Am J Gastroenterol. 2002 Sep;97(9):2231-8.

PMID:
12358238
27.

Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production.

Yamaoka Y, Kikuchi S, el-Zimaity HM, Gutierrez O, Osato MS, Graham DY.

Gastroenterology. 2002 Aug;123(2):414-24.

PMID:
12145793
28.

Patterns of gastric atrophy in intestinal type gastric carcinoma.

El-Zimaity HM, Ota H, Graham DY, Akamatsu T, Katsuyama T.

Cancer. 2002 Mar 1;94(5):1428-36.

29.

NSAID gastric ulceration: predictive value of gastric pH, mucosal density of polymorphonuclear leukocytes, or levels of IL-8 or nitrite.

Shiotani A, Yamaoka Y, El-Zimaity HM, Saeed MA, Qureshi WA, Graham DY.

Dig Dis Sci. 2002 Jan;47(1):38-43.

PMID:
11852880
30.

Gastric intestinal metaplasia: subtypes and natural history.

El-Zimaity HM, Ramchatesingh J, Saeed MA, Graham DY.

J Clin Pathol. 2001 Sep;54(9):679-83.

31.

Ultrastructural evidence of in vivo phagocytosis of Helicobacter pylori.

El-Zimaity HM, Graham DY.

Ultrastruct Pathol. 2001 Mar-Apr;25(2):159. No abstract available.

PMID:
11407530
32.

Detection of Mycobacterium avium subspecies paratuberculosis in Crohn's diseased tissues by in situ hybridization.

Hulten K, El-Zimaity HM, Karttunen TJ, Almashhrawi A, Schwartz MR, Graham DY, El-Zaatari FA.

Am J Gastroenterol. 2001 May;96(5):1529-35.

PMID:
11374694
33.
34.

Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance.

Graham DY, Saeed MA, Hoffman J, El-Zimaity HM, Kwon DH, Osato MS.

Aliment Pharmacol Ther. 2001 Apr;15(4):513-8.

35.

Geographic differences in the distribution of intestinal metaplasia in duodenal ulcer patients.

El-Zimaity HMT, Gutierrez O, Kim JG, Akamatsu T, G├╝rer IE, Simjee AE, Graham DY.

Am J Gastroenterol. 2001 Mar;96(3):666-72.

PMID:
11280531
36.

Accurate diagnosis of Helicobacter pylori with biopsy.

el-Zimaity HM.

Gastroenterol Clin North Am. 2000 Dec;29(4):863-9. Review.

PMID:
11190070
37.

Review article: Mycobacterium avium subsp. paratuberculosis as one cause of Crohn's disease.

Chamberlin W, Graham DY, Hulten K, El-Zimaity HM, Schwartz MR, Naser S, Shafran I, El-Zaatari FA.

Aliment Pharmacol Ther. 2001 Mar;15(3):337-46. Review.

38.

In situ hybridization method for studies of cell wall deficient M. paratuberculosis in tissue samples.

Hulten K, Karttunen TJ, El-Zimaity HM, Naser SA, Almashhrawi A, Graham DY, El-Zaatari FA.

Vet Microbiol. 2000 Dec 20;77(3-4):513-8.

PMID:
11118736
39.

Modified triple stain (carbol fuchsin/alcian blue/hematoxylin-eosin) for the identification of Helicobacter pylori.

El-Zimaity HM.

Arch Pathol Lab Med. 2000 Oct;124(10):1416-7. No abstract available.

PMID:
11035566
40.

Identification of cell wall deficient forms of M. avium subsp. paratuberculosis in paraffin embedded tissues from animals with Johne's disease by in situ hybridization.

Hulten K, Karttunen TJ, El-Zimaity HM, Naser SA, Collins MT, Graham DY, El-Zaatari FA.

J Microbiol Methods. 2000 Oct;42(2):185-95.

PMID:
11018275
41.

The gastric cardia in gastro-oesophageal disease.

el-Zimaity HM, Verghese VJ, Ramchatesingh J, Graham DY.

J Clin Pathol. 2000 Aug;53(8):619-25.

42.

Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study.

Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson SY, Kwon DH, El-Zimaity HM.

Aliment Pharmacol Ther. 2000 Jun;14(6):745-50.

43.

Sustained increase in gastric antral epithelial cell proliferation despite cure of Helicobacter pylori infection.

El-Zimaity HM, Graham DY, Genta RM, Lechago J.

Am J Gastroenterol. 2000 Apr;95(4):930-5.

PMID:
10763940
44.

A reliable method for the simultaneous identification of H pylori and gastric metaplasia in the duodenum.

el-Zimaity HM, Wu J, Akamatsu T, Graham DY.

J Clin Pathol. 1999 Dec;52(12):914-6.

45.

Modified Genta triple stain for identifying Helicobacter pylori.

el-Zimaity HM, Wu J, Graham DY.

J Clin Pathol. 1999 Sep;52(9):693-4.

46.

Furazolidone combination therapies for Helicobacter pylori infection in the United States.

Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson SY, El-Zimaity HM.

Aliment Pharmacol Ther. 2000 Feb;14(2):211-5.

47.

The differential diagnosis of early gastric mucosa-associated lymphoma: polymerase chain reaction and paraffin section immunophenotyping.

El-Zimaity HM, El-Zaatari FA, Dore MP, Oweiss S, Gutierrez O, Yuksul M, Ramchatesingh J, Graham DY.

Mod Pathol. 1999 Sep;12(9):885-93.

PMID:
10496597
48.

Relationship between the cagA 3' repeat region of Helicobacter pylori, gastric histology, and susceptibility to low pH.

Yamaoka Y, El-Zimaity HM, Gutierrez O, Figura N, Kim JG, Kodama T, Kashima K, Graham DY.

Gastroenterology. 1999 Aug;117(2):342-9. Erratum in: Gastroenterology 1999 Oct;117(4):1033. Kim JK [corrected to Kim JG].

PMID:
10419915
49.

Endoscopic resection for early gastric cancer: possibilities and limitations.

El-Zimaity HM, Ota H.

J Clin Gastroenterol. 1999 Jul;29(1):5-6. No abstract available.

PMID:
10405222
50.

Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection.

Graham DY, Hoffman J, Anderson SY, Qureshi W, Osato MS, El-Zimaity HM.

Aliment Pharmacol Ther. 1999 Feb;13(2):169-72.

Supplemental Content

Loading ...
Support Center